13 results on '"Bagella,Paola"'
Search Results
2. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance
- Author
-
Madeddu, Giordano, De Socio, Giuseppe V.L., Ricci, Elena, Quirino, Tiziana, Orofino, Giancarlo, Carenzi, Laura, Franzetti, Marco, Parruti, Giustino, Martinelli, Canio, Vichi, Francesca, Penco, Giovanni, Dentone, Chiara, Celesia, Benedetto Maurizio, Maggi, Paolo, Libertone, Raffaella, Bagella, Paola, Di Biagio, Antonio, and Bonfanti, Paolo
- Published
- 2015
- Full Text
- View/download PDF
3. Human Papilloma Virus Infections in Men: Focus on Vaccination and Treatment Options
- Author
-
Bagella, Paola, Fiore, Vito, Caruana, Giorgia, Ortu, Silvia, Babudieri, Sergio, and Madeddu, Giordano
- Published
- 2017
- Full Text
- View/download PDF
4. Mediterranean spotted fever-like illness in Sardinia, Italy: a clinical and microbiological study
- Author
-
Madeddu, Giordano, Fiore, Vito, Mancini, Fabiola, Caddeo, Antonello, Ciervo, Alessandra, Babudieri, Sergio, Masala, Giovanna, Bagella, Paola, Nunnari, Giuseppe, Rezza, Giovanni, and Mura, Maria Stella
- Published
- 2016
- Full Text
- View/download PDF
5. HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project.
- Author
-
De Vito, Andrea, Colpani, Agnese, Mameli, Maria Sabrina, Bagella, Paola, Fiore, Vito, Fozza, Claudio, Montesu, Maria Antonia, Fois, Alessandro Giuseppe, Filigheddu, Fabiana, Manzoni, Noemi, Putzu, Carlo, Babudieri, Sergio, and Madeddu, Giordano
- Subjects
HIV infections ,HIV infection transmission ,HIV-positive persons ,UNIVERSITY hospitals ,NON-communicable diseases - Abstract
In 2014, UNAIDS launched renewed global targets for HIV control to achieve by 2025, known as "the three 95": 95% of people living with HIV (PWH) diagnosed, of which 95% are receiving treatment, of which 95% are on sustained virological suppression. In Italy, new HIV diagnoses have been steadily decreasing since 2012. However, in 2020, 41% of new diagnoses presented with less than 200 CD4+ cells/µL and 60% with less than 350 CD4+ cells/µL. Implementing testing and early treatment is a key strategy to prevent AIDS, late presentation, and HIV transmission. We selected non-Infectious Diseases Units based on the European project HIDES and engaged colleagues in a condition-guided HIV screening strategy. We enrolled 300 patients, of which 202 were males (67.3%) and 98 were females (32.7%). Most of the screening was performed in Infectious Diseases (ID) and Hematologic wards. In total, we diagnosed eleven new HIV infections with a hospital prevalence in the study population of 3.7%. Five (45.4%) had a CD4 count <100/mm
3 , one (9.1%) <200/mm3 , and one (9.1%) <300/mm3 . Regarding risk factors, 81.8% declared having had unprotected sexual intercourse and 54.5% were heterosexual. All patients promptly started a combination antiretroviral regimen and 10 (90.9%) obtained an undetectable HIV-RNA status. Eight of the eleven (72.7%) patients are currently on follow-up in our outpatient clinic. A proactive indicator disease-guided screening can help avoid missed opportunities to diagnose HIV infection in a hospital setting. Implementing this kind of intervention could favor early diagnosis and access to treatment. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study.
- Author
-
Fiore, Vito, De Vito, Andrea, Bagella, Paola, Princic, Elija, Mariani, Anna Antonella, Denti, Lucia, Fois, Alessandro Giuseppe, Madeddu, Giordano, Babudieri, Sergio, and Maida, Ivana
- Subjects
COVID-19 ,DIETARY supplements ,CHOLECALCIFEROL ,VITAMIN D ,NONINVASIVE ventilation ,CALCIUM supplements ,PROGNOSIS ,SURVIVAL rate - Abstract
Objectives: Our study aimed to evaluate the usefulness of Vitamin D3 (VitD3) among patients hospitalized for COVID-19. The primary endpoint was to evaluate the difference in survival rates between patients receiving and not VitD3. The secondary endpoints were to evaluate clinical outcomes, such as needing non-invasive ventilation (NIV), ICU transfer, and laboratory findings (inflammatory parameters). Methods: We conducted a retrospective, monocentric matched-cohort study, including patients attending our ward for COVID-19. Patients were divided into two groups depending on VitD3 administration (Group A) or not (Group B) among patients with low VitD levels (defined as blood levels < 30 ng/mL), which depended on physicians' judgment. Our internal protocol provides VitD3 100,000 UI/daily for two days. Findings: 58 patients were included in Group A, and 58 in Group B. Patients were matched for age, sex, comorbidities, COVID-19-related symptoms, PaO2/FiO2 ratio, blood exams, and medical treatments. Regarding the principal endpoint, there was a statistically significant difference between the two groups in survival rates [Group A vs. Group B = 3 vs. 11 (p = 0.042)]. When considering secondary endpoints, Group A patients were less likely to undergo NIV [Group A vs. Group B = 12 vs. 23 (p = 0.026)] and showed an improvement in almost all inflammatory parameters. Conclusions: The link between VitD3 deficiency and the clinical course of COVID-19 during hospitalization suggests that VitD3 level is a useful prognostic marker. Considering the safety of supplementation and the low cost, VitD3 replacement should be considered among SARS-CoV-2 infected patients needing hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project.
- Author
-
Bagella, Paola, Squillace, Nicola, Ricci, Elena, Gulminetti, Roberto, Socio, Giuseppe Vittorio De, Taramasso, Lucia, Pellicanò, Giovanni, Menzaghi, Barbara, Celesia, Benedetto Maurizio, Dentone, Chiara, Orofino, Giancarlo, Bonfanti, Paolo, and Madeddu, Giordano
- Subjects
NON-nucleoside reverse transcriptase inhibitors ,HIGH density lipoproteins ,LIPIDS - Abstract
Introduction: Metabolic disorders are common amongst HIV-infected patients. Data from real-life setting on the impact of DTG/ABC/3TC in virologically suppressed HIV-infected patients are scarce. Methods: We investigated the modification of metabolic profile including fasting glucose, lipid profile and markers of insulin resistance (IR) in experienced patients switching from a boosted protease inhibitors (bPI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to DTG/ABC/3TC in a prospective, observational, multicenter study. Results: We enrolled 131 HIV-infected patients, of whom 91 (69.5%) males, mean age was 50.5±10.6 years. CDC stage was A in 66 (50.4%) patients, of whom 91 (69.5%) had acquired HIV through sexual contacts. The previous regimen was bPI-based in 79 patients (60.3%) and NNRTI-based in 52 (39.7%). Patients switching from NNRTI showed a significant reduction at week 24 in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL). Triglycerides/high-density lipoprotein cholesterol (TG/HDL) ratio, HDL, median TG and TG/HDL ratio did not show significant modification during follow-up times. Among patients switching from a bPI, we observed a significant reduction in TC and LDL at both follow-up times and a slight increase in HDL. Triglycerides/HDL ratio, median TG and TG/HDL ratio showed a decrease over time that became significant at weeks 24 and 48. Blood glucose levels did not significantly vary during the observation period in patients switching from both bPI and NNRTI-based regimens. Conclusion: Our data suggest an improvement in lipid profile and TG/HDL ratio in pretreated HIV-1-infected patients who switched to DTG/ABC/3TC over 48 weeks, especially in those previously receiving a bPI-based regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.
- Author
-
Bagella, Paola, Socio, Giuseppe VL De, Ricci, Elena, Menzaghi, Barbara, Martinelli, Canio, Squillace, Nicola, Maggi, Paolo, Orofino, Giancarlo, Calza, Leonardo, Carenzi, Laura, Celesia, Benedetto Maurizio, Penco, Giovanni, Biagio, Antonio Di, Valsecchi, Laura, Vichi, Francesca, Colombo, Valeria, Parruti, Giustino, Dentone, Chiara, Falasca, Katia, and Bonfanti, Paolo
- Subjects
RILPIVIRINE ,MEDICATION safety ,DRUG efficacy ,ANTIRETROVIRAL agents ,THERAPEUTICS ,HIV infections ,DRUG side effects - Abstract
Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, mean CD4 600 ± 327 cell/µL, mean HIV-RNA 3.80 ± 1.15 log
10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade =3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Enzyme Biosensors for Biomedical Applications: Strategies for Safeguarding Analytical Performances in Biological Fluids.
- Author
-
Rocchitta, Gaia, Spanu, Angela, Babudieri, Sergio, Latte, Gavinella, Madeddu, Giordano, Galleri, Grazia, Nuvoli, Susanna, Bagella, Paola, Demartis, Maria Ilaria, Fiore, Vito, Manetti, Roberto, and Serra, Pier Andrea
- Subjects
BIOSENSORS ,DETECTORS ,MEDICAL equipment ,AMPEROMETRIC sensors ,ELECTROCHEMICAL sensors ,CONDUCTOMETRIC analysis - Abstract
Enzyme-based chemical biosensors are based on biological recognition. In order to operate, the enzymes must be available to catalyze a specific biochemical reaction and be stable under the normal operating conditions of the biosensor. Design of biosensors is based on knowledge about the target analyte, as well as the complexity of the matrix in which the analyte has to be quantified. This article reviews the problems resulting from the interaction of enzyme-based amperometric biosensors with complex biological matrices containing the target analyte(s). One of the most challenging disadvantages of amperometric enzyme-based biosensor detection is signal reduction from fouling agents and interference from chemicals present in the sample matrix. This article, therefore, investigates the principles of functioning of enzymatic biosensors, their analytical performance over time and the strategies used to optimize their performance. Moreover, the composition of biological fluids as a function of their interaction with biosensing will be presented. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Tache Noire in a Patient with Acute Q Fever.
- Author
-
Fiore, Vito, Mancini, Fabiola, Ciervo, Alessandra, Bagella, Paola, Peruzzu, Francesca, Nunnari, Giuseppe, Deiana, Giovanni Andrea, Rezza, Giovanni, Babudieri, Sergio, and Madeddu, Giordano
- Subjects
Q fever ,BOUTONNEUSE fever ,DOXYCYCLINE ,ROUTINE diagnostic tests ,COXIELLA burnetii - Abstract
Objective: To describe a rare case of acute Q fever with tache noire.Clinical Presentation and Intervention: A 51-year-old man experienced acute Q fever showing tache noire, generally considered a pathognomonic sign of Mediterranean spotted fever (MSF) and MSF-like illness, but not a clinical feature of Q fever. The patient was treated with doxycycline 100 mg every 12 h.Conclusion: In the Mediterranean area, tache noire should be considered pathognomonic of MSF but it should not rule out Q fever. Clinical diagnosis should be supported by accurate laboratory diagnostic tests to guide proper management. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project
- Author
-
Bagella, P., De Socio, Gvl., Ricci, E., Menzaghi, B., Martinelli, C., Squillace, N., Maggi, P., Orofino, G., Calza, L., Carenzi, L., Belesia, B. M., Penco, G., Di Biagio, A., Valsecchi, L., Vichi, F., Colombo, V., Parruti, G., Dentone, C., Falasca, K., Bonfanti, P., Madeddu, G., Study Group Italy, On behalf of the C. I. S. A. I., Nunnari, G., Pellicano', Giovanni Francesco, Bagella, P, De Socio, G, Ricci, E, Menzaghi, B, Martinelli, C, Squillace, N, Maggi, P, Orofino, G, Calza, L, Carenzi, L, Celesia, B, Penco, G, Di Biagio, A, Valsecchi, L, Vichi, F, Colombo, V, Parruti, G, Dentone, C, Falasca, K, Bonfanti, P, Madeddu, G, Bagella, Paola, De Socio, Giuseppe V. L., Ricci, Elena, Menzaghi, Barbara, Martinelli, Canio, Squillace, Nicola, Maggi, Paolo, Orofino, Giancarlo, Calza, Leonardo, Carenzi, Laura, Celesia, Benedetto Maurizio, Penco, Giovanni, Di Biagio, Antonio, Valsecchi, Laura, Vichi, Francesca, Colombo, Valeria, Parruti, Giustino, Dentone, Chiara, Falasca, Katia, Bonfanti, Paolo, and Madeddu, Giordano
- Subjects
0301 basic medicine ,safety ,Combination antiretroviral therapy ,NNRTI ,medicine.medical_specialty ,Cohort study ,Experienced patients ,HIV-1 ,Naive ,efficacy ,Infectious Disease ,Experienced patient ,Gastroenterology ,lcsh:Infectious and parasitic diseases ,rilpivirine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Median follow-up ,Internal medicine ,medicine ,Pharmacology (medical) ,lcsh:RC109-216 ,030212 general & internal medicine ,Adverse effect ,HIV-1, combination antiretroviral therapy, NNRTI, cohort study, naive, experienced patients ,Original Research ,Pharmacology ,medicine.diagnostic_test ,business.industry ,030112 virology ,Antiretroviral therapy ,Discontinuation ,combination antiretroviral therapy ,Infectious Diseases ,Tolerability ,chemistry ,Infection and Drug Resistance ,Rilpivirine ,Lipid profile ,business - Abstract
Paola Bagella,1 Giuseppe VL De Socio,2 Elena Ricci,3 Barbara Menzaghi,4 Canio Martinelli,5 Nicola Squillace,6 Paolo Maggi,7 Giancarlo Orofino,8 Leonardo Calza,9 Laura Carenzi,3 Benedetto Maurizio Celesia,10 Giovanni Penco,11 Antonio Di Biagio,12 Laura Valsecchi,3 Francesca Vichi,13 Valeria Colombo,14 Giustino Parruti,15 Chiara Dentone,16 Katia Falasca,17 Paolo Bonfanti,18 Giordano Madeddu1 On behalf of the C.I.S.A.I. Study Group, Italy 1Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 2Infectious Diseases Unit, Department of Medicine, Azienda Ospedaliero-Universitaria di Perugia, Santa Maria Hospital, Perugia, Italy; 3Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy; 4Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy; 5Unit of Infectious and Tropical Diseases, Careggi Hospital Florence, Florence, Italy; 6Infectious Diseases Unit, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 7Infectious Diseases Clinic, University of Bari, Policlinico Consorziale, Bari, Italy; 8Amedeo di Savoia Hospital Unit of Infectious Diseases, Torino, Italy; 9University of Bologna, Department of Infectious Diseases, S. Orsola Malpighi Hospital, Bologna, Italy; 10Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy; 11Infectious Diseases Unit, Galliera Hospital, Genoa, Italy; 12Unit of Infectious Diseases, IRCCS San Martino Hospital – IST, Genoa, Italy; 13Infectious Diseases Unit, Santa Maria Annunziata Hospital, Florence, Italy; 14Infectious Diseases Unit, University of Milan, DIBIC Luigi Sacco, Milan, Italy; 15Unit of Infectious Diseases, Pescara Hospital, Pescara, Italy; 16Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy; 17Infectious Diseases Unit, University of Chieti, Chieti, Italy; 18Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy Abstract: Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored. Keywords: HIV-1, combination antiretroviral therapy, NNRTI, cohort study, naive, experienced patients
- Published
- 2018
12. Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy.
- Author
-
Madeddu, Giordano, Fiori, Maria Laura, Ena, Pasquale, Riu, Francesco, Lovigu, Carla, Nunnari, Giuseppe, Bagella, Paola, Maida, Ivana, Babudieri, Sergio, and Mura, Maria Stella
- Subjects
- *
MUCOCUTANEOUS leishmaniasis , *HIV infections , *SARDINIANS , *ANTIRETROVIRAL agents , *HISTOPATHOLOGY , *DISEASES - Abstract
Abstract: Leishmaniasis is endemic in Sardinia but only cutaneous and visceral cases have been reported to date. We report a case of mucocutaneous leishmaniasis as presentation of HIV infection in a Sardinian patient who had never visited endemic areas. Serological and clinical diagnosis was cytologically and histopathologically confirmed. The patient had a good response to treatment with liposomal amphotericin combined with highly active antiretroviral therapy without recurrences after four years. Our case report highlights the need to better assess the circulation of species, risk factors and clinical spectrum of Leishmania infection in the Italian Mediterranean islands. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
13. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
- Author
-
Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, and Paliogiannis P
- Subjects
- Clinical Trials as Topic, Feedback, Physiological, High-Throughput Nucleotide Sequencing, Humans, Signal Transduction drug effects, Targeted Gene Repair, Antineoplastic Agents, Immunological therapeutic use, Bile Duct Neoplasms drug therapy, Bile Duct Neoplasms genetics, Cholangiocarcinoma drug therapy, Cholangiocarcinoma genetics, Enzyme Inhibitors therapeutic use, Immunotherapy, Molecular Targeted Therapy
- Abstract
Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies., Competing Interests: The authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.